SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/237113"
 

Search: onr:"swepub:oai:gup.ub.gu.se/237113" > Adjuvant ovarian fu...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Phillips, K. A. (author)

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • 2016-04-19
  • Springer Science and Business Media LLC,2016

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/237113
  • https://gup.ub.gu.se/publication/237113URI
  • https://doi.org/10.1038/bjc.2016.71DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer. Methods: The Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive breast cancer to 5 years adjuvant endocrine therapy with tamoxifen + OFS, exemestane + OFS or tamoxifen alone. The Co-SOFT substudy assessed objective cognitive function and patient reported outcomes at randomisation (T0), and 1 year later (T1); the primary endpoint was change in global cognitive function, measured by the composite objective cognitive function score. Data were compared for the pooled tamoxifen + OFS and exemestane + OFS groups vs the tamoxifen alone group using the Wilcoxon rank-sum test. Results: Of 86 participants, 74 underwent both T0 and T1 cognitive testing; 54 randomised to OFS+ either tamoxifen (28) or exemestane (26) and 20 randomised to tamoxifen alone. There was no significant difference in the changes in the composite cognitive function scores between the OFS+ tamoxifen or exemestane groups and the tamoxifen group (mean +/- s.d., -0.21 +/- 0.92 vs -0.04 +/- 0.49, respectively, P = 0.71, effect size = -0.20), regardless of prior chemotherapy status, and adjusting for baseline characteristics. Conclusions: The Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral endocrine therapy substantially affects global cognitive function.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Regan, M. M. (author)
  • Ribi, K. (author)
  • Francis, P. A. (author)
  • Puglisi, F. (author)
  • Bellet, M. (author)
  • Spazzapan, S. (author)
  • Karlsson, Per,1963Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology(Swepub:gu)xkperd (author)
  • Budman, D. R. (author)
  • Zaman, K. (author)
  • Abdi, E. A. (author)
  • Domchek, S. M. (author)
  • Feng, Y. (author)
  • Price, K. N. (author)
  • Coates, A. S. (author)
  • Gelber, R. D. (author)
  • Maruff, P. (author)
  • Boyle, F. (author)
  • Forbes, J. F. (author)
  • Ahles, T. (author)
  • Fleming, G. F. (author)
  • Bernhard, J. (author)
  • Co, Soft Investigators (author)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för onkologi (creator_code:org_t)

Related titles

  • In:British Journal of Cancer: Springer Science and Business Media LLC114:9, s. 956-9640007-09201532-1827

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view